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Abstract Magnetic resonance imaging (MRI) is a useful
tool for evaluating disease activity and therapeutic efﬁcacy
in rheumatoid arthritis (RA). However, conventional
whole-body MRI is inconvenient on several levels. We
have therefore developed a new low-ﬁeld extremity MRI
(compact MRI, cMRI) and examined its clinical utility.
Thirteen RA patients treated with anti-tumor necrosis fac-
tor (TNF) biologics were included in the study. The MRI
was performed twice using a 0.21-T extremity MRI system.
The MRI images were scored using our proposed cMRI
scoring system, which we devised with reference to the
Outcome Measures in Rheumatology Clinical Trials RA
MRI score (OMERACT RAMRIS). In our cMRI scoring
system, synovitis, bone edema, and bone erosion are sep-
arately graded on a scale from 0 to 3 by imaging over the
whole hand, including the proximal interphalangeal joint.
The total cMRI score (cMRIS) is then obtained by calcu-
lating the total bone erosion score 9 1.5 ? total bone
edema score 9 1.25 ? total synovitis score. In this study,
one patient showed a progression of bone destruction even
under low clinical activity, as assessed by the disease
activity score on 28 joints (DAS28); however, another
patient’s cMRIS decreased concurrently with the decrease
in DAS28, with the positive correlation observed between
DDAS28 and DcMRIS (R = 0.055, P\0.05). We con-
clude that cMRI and cMRIS are useful for assessing total
disease activity and as a method linking MRI image eval-
uation to clinical evaluation.
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Introduction
Rheumatoid arthritis (RA) is a systemic inﬂammatory
autoimmune disease that predominantly affects the syno-
vial membranes of joints. Persistent inﬂammation or
synovitis leads to pannus formation and, ultimately, bone
destruction. A therapeutic window [1] does exist early in
the RA course; therefore, the development of better
methods for the early diagnosis and treatment of RA is one
of the prime objectives of rheumatologists. Conventional
radiography is currently the major tool for diagnosing RA
and monitoring the progression of joint destruction. How-
ever, because this technique visualizes only late signs of
preceding disease activity, other diagnostic tools, such as
magnetic resonance imaging (MRI), have been the focus of
increasing attention in recent years. Magnetic resonance
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DOI 10.1007/s10165-009-0172-2imaging is three- to sevenfold more sensitive than con-
ventional radiography in terms of detecting joint erosion in
early-stage RA [2, 3]. It can also detect synovitis, bone
edema, and tenosynovitis that is not visible on conventional
radiographic scans [4, 5]. Synovitis is among the earliest
abnormalities observed in RA and is, in many cases,
already apparent before a patient complains of joint pain or
shows elevated serum C-reactive protein (CRP). The
degree of bone marrow edema in metacarpalphalangeal
(MCP) and wrist joints has recently been reported to be a
more important predicator of radiographic progression in
early RA than the degree of synovitis, erosion, or disease
activity score based on 28 joints (DAS28) [6]. Evaluating
bone edema by MRI may therefore assist clinicians in
determining whether a patient should receive early and
aggressive treatment to avoid subsequent joint damage.
While MRI may provide signiﬁcant information about
the course of RA not obtainable by conventional radiog-
raphy, conventional whole-body, high-ﬁeld MRI is more
expensive in terms of both startup costs and maintenance
fees, and it is not always convenient. In addition, claus-
trophobic patients and those suffering severe joint pain are
sometimes unable to complete the examination. Low-ﬁeld
extremity MRI was recently developed to address these
limitations; it is now commercially available and has been
used clinically to evaluate RA. Low-ﬁeld extremity MRI
offers adequate performance at a lower cost and with
greater comfort and convenience to the patient than con-
ventional MRI [7, 8]. One strong disadvantage of this tool,
however, is that the ﬁeld of view (FOV) is too small to
assess hand and wrist joints in one examination or in one
sequence—and RA usually affects the wrist to proximal
interphalangeal (PIP) joints. This is a major limiting factor
in the success of low-ﬁeld MRI for diagnosing of RA or
assessing disease activity.
We have recently developed a new low-ﬁeld extremity
MRI system with a FOV large enough to simultaneously
assess the entire wrist to PIP joint area. In the study
reported here, we examined the clinical value of our low-
ﬁeld MRI system for assessing disease activity in RA
patients treated with anti-tumor necrosis factor (TNF)
biologics using the original scoring system.
Patients and methods
Patients and clinical assessments
Thirteen RA outpatients were enrolled in the study (two
men and 11 women). The mean disease duration at eval-
uation was 6.2 years. Seven patients were treated with
inﬂiximab (IFX) and six with etanercept (ETN). Clinical
disease activity was determined using the DAS28–CRP.
Eleven patients had moderate or high disease activity
before receiving anti-TNF biologics; the remaining patients
had low clinical disease activity but showed bone des-
truction in the wrists, which had worsened signiﬁcantly
within the past year, as assessed by radiography. The
IFX group also received an average methotrexate dose of
8 mg/week, with six patients also treated with prednisolone
(average dose 7.1 mg/day). In the ETN group, four patients
also received methotrexate (average dose 5 mg/week),
and all six patients were taking prednisolone (average
dose 5.3 mg/day). Table 1 presents additional sociodemo-
graphic data on these patients. All patients underwent two
MRI assessments; the ﬁrst was carried out at the time of
starting the biologics (IFX group patients 5–7; ETN group
patient 6) or within 7 and 9 months from the initial infusion
of IFX and ETN (IFX group patients 1–4 and ETN group
patients 1–5), respectively, and the second MRI assessment
was within 8–16 months and 5–23 months from the ﬁrst
infusion for the respective groups.
New low-ﬁeld extremity MRI system and MRI
protocols
The new system is called compact MRI (cMRI). It com-
prises a permanent magnet, a gradient coil set, and an MRI
console, generating a magnetic ﬁeld strength of 0.21 T.
The system occupies a total installation space of 4 m
2. The
magnet is placed in an electromagnetic shield room [1.6
(W) 9 2.0 (H) 9 2.4 (D)] to prevent external noise.
Patients sit in front of the magnet and insert one hand into
the radio frequency (RF) coil for MR imaging. Coronal
three-dimensional (3-D) gradient recalled echo T1-weigh-
ted images [repetition time (TR)/echo time (TE) =
50/9 ms] were obtained with an image matrix size at
512 9 384 9 32, FOV of 20.48 9 15.36 9 6.4 cm, and a
scan time of 7 min and 5 s. Coronal 3D fast short tau
inversion recovery (STIR) images [TR/TE/inversion time
(TI) = 1000/60/100 ms] were also obtained with an
image matrix size of 256 9 256 9 8, FOV at 20.48 9
20.48 9 6.4 cm, and a scan time of 8 min and 30 s. Both
hands were scanned in all patients. The total examination
time, including patient positioning, required about 40 min.
Image evaluation and proposed compact MRI score
Magnetic resonance imaging ﬁndings are currently scored
using the RA MRI scoring system (RAMRIS) as reported in
the Outcome Measures in Rheumatology Clinical Trials
(OMERACT) [9]. However, the RAMRIS system requires a
two-dimensional (2-D) analysis, and our cMRI system can
analyze only the coronary section; consequently, RAMRIS
cannot be used in our system. Our modiﬁed MRI system can
visualize joints from the wrist to PIP in only one image. We
Mod Rheumatol (2009) 19:358–365 359
123therefore evaluated the images using our original scoring
system, to obtain a compact MRI score (cMRIS) referenced
to RAMRIS. The cMRIS scores the degree of bone erosion,
bone marrow edema, and synovitis in both hands. In this
study, the MRI images were reviewed by one radiologist,
who is a Board-certiﬁed radiologist (by the authority of the
Japan Radiological Society), and by more than two rheu-
matologists. All patients’ information was blinded. Bone
erosion and edema were deﬁned using the OMERACT MRI
joint pathology deﬁnition [10]. Bone erosion was deﬁned by
the presence of a sharply marginated bone region that was
imaged as a loss of normal signal intensity of cortical bone
and a loss of normal high signal characteristics, visible in
twoplanes, withacortical breakseeninatleastoneplaneon
the T1-weighted image. Bone edema was deﬁned a lesion
within the trabecular bone, with ill-deﬁned margins and
signal characteristics consistent with increased water con-
tent that was imaged as high-intense signal on STIR and a
low-intense signal on the T1-weighted image. Since we did
not use gadolinium enhancement, synovitis was deﬁned a
highsignalintensityonSTIRthatseemedanatomicallytobe
thesynovialarea.TheRAMRISratesboneerosionfrom0to
10 by volume, while our scoring system rates bone erosion
on a scale from 0 to 3 by volume. Bone edema and synovitis
were scored on the same scale as RAMRIS. The PIP joints
were scored by the same method used for the evaluating the
MCP joints. This study evaluated 23 bones and 11 joints
(Fig. 1). Bone erosion and edema were estimated in one to
ﬁve MCP joints and one to ﬁve carpometacarpal (CM)
joints, in two to ﬁve proximal and distal PIP joints,and in all
wrist bones, except for the pisiforme, distal radius, and head
of ulna. In the PIP and MCP joints, we evaluated each
proximaland each distal side separately. andthe scoreof the
worse side was counted. Thus, the total estimation site of
bone erosion and edema was 32. Synovitis, which was also
scored on a scale from 0 to 3, was evaluated in two to ﬁve
PIP joints, one to ﬁve MCP joints, and in the intercarpal
and distal radioulnar joints. However, the intercarpal joint
synovitisscorewasdoubledbecauseofitslargevolume.The
overall score was calculated as follows: total synovitis
score ? 1.25 9 totalboneedema score ? 1.5 9 totalbone
erosion score [maximum total bone erosion score 207
(3 9 23 9 1.5 9 2), maximum total bone edema score
172.5 (3 9 23 9 1.25 9 2), maximum total synovitis
score 72 {(3 9 10 ? 3 9 1 9 2) 9 2}; maximum cMRIS
451.5]. Further details of the scoring system are provided in
Table 2.
Statistical analysis
The correlation between the changes in cMRIS (DcMRIS)
and the DAS28–CRP (DDAS28) values was evaluated by
Pearson’s correlation coefﬁcient test. A value of P\0.05
was considered to be signiﬁcant.
Results
Evaluation of DAS28-CRP
The DAS28–CRP was evaluated prior to the biologics
treatment and at the time of ﬁrst and second MRI
Table 1 Patients’
demographics
F Female, M male,
MTX methotrexate, PSL
prednisolone, DMARDs disease-
modifying antirheumatic drugs,
SASP salazosulfapyridine, ACT
Actarit, BC bucillamine
a Stage was determined
according to the Steinblocker’s
classiﬁcation, and class was
determined according to the
Hochberg’s classiﬁcation
Patient Age
(years)
Sex Disease duration
(years)
Stage
a Class
a MTX
(mg/week)
PSL
(mg/day)
Other
DMARDs
Inﬂiximab group
1 51 F 1 2 2 10 10 SASP
25 8 F 5 2 1 8 0 B C
33 1 F 6 3 3 8 4
4 48 F 11 4 3 6 15
5 55 F 14 3 3 8 12.5
63 0 F 2 1 1 8 4
73 9 F 4 3 2 8 4
Average 44.6 6.1 2 2 8 7.1
Etanercept group
16 8 M 3 4 2 8 5
21 8 F 2 2 1 1 2 6
3 54 M 3 3 2 4 6 SASP
4 59 F 12 4 3 0 10 SASP, ACT
54 2 F 1 0 2 1 0 4
63 3 F 8 4 2 6 1
Average 45.7 6 3 2 5 5.3
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123examinations. All patients of both treatment groups (IFX
and ETN) except one showed a moderate-to-good
response, as assessed by DAS28–CRP, and none showed a
recurrence of disease activity (Fig. 2).
Changes in cMRI score
Figure 2 and Table 3 provide details on the MRI scores
calculated from the ﬁrst and second imaging examinations
for all patients. The ﬁrst imaging identiﬁed seven patients
with synovitis and three with bone edema in the ﬁnger
joints. All patients showed bone erosion in the ﬁrst and
second imaging. However, erosion of the ﬁnger joints did
not worsen in any of the patients included in this study,
with ten of 13 patients showing an improvement over the
intervening time period. Synovitis was present in the wrist
joints of 12 patients at the ﬁrst imaging, and although
persistent, the second imaging showed improved synovitis
in the wrist joints in most patients. Ten of the 13 patients
showed bone edema in the wrist joint at the ﬁrst imaging;
by the second imaging, seven of these patients showed
improvement, and three patients showed deterioration.
Patient 1 of the IFX group showed remarkable joint
destructions over the treatment time, while the others
remained the same or showed a slight improvement.
Relationship between cMRIS and DAS28-CRP
We evaluated the correlation between DcMRIS and
DDAS28 in our small cohort and observed a positive
correlation between the two scores (R = 0.055, P\0.05;
Fig. 3). However, one patient (IFX group patient 1) showed
a very small change in the DAS28–CRP (2.66–2.83),
Fig. 1 Sites evaluated in calculating the compact magnetic resonance
imaging (MRI) score. In this scoring system, 23 bones and 16 joints
were evaluated. Pisiforme was excluded from the wrist bone
evaluation. Bone erosion and edema were evaluated in 32 sites, and
synovitis was evaluated in 11 sites. The score calculation is provided
in detail in Table 2
Table 2 Compact MRI score (cMRIS) used in this study
Bone erosion
Sites Each wrist bone (except pisiforme), PIP (II–V),
MCP (I–V), CM (I–V), carpal bones, distal radius
and distal ulna, total of 23 bones, was scored
separately.
Methods Erosion was scored from 0 to 3, based on the
proportion of the eroded bone relative to the
assessed bone volume
0: no erosion, 1: 1–33% of bone eroded, 2: 34–66%
of bone eroded, 3: 67–100% of bone eroded.
PIP and MCP joint was evaluated each proximal and
distal side separately, and the score of the worse
side was counted.
Bone edema
Sites Each wrist bone (except pisiforme), PIP (II–V),
MCP (I–V), CM (I–V), carpal bones, distal radius
and head of ulna was scored separately.
Methods Bone edema was scored 0–3 according to the
volume of edema relative to the assessed bone
volume. The assessed bone volume in long bones
was from the articular surface (or, if absent, its
best estimated position) to a depth of 1 cm, while
it was the whole bone in carpal bones
0: no edema, 1: 1–33% of bone edematous, 2:
34–66% of bone edematous, 3: 67–100% of bone
edematous.
The PIP and MCP joints were evaluated on each
proximal and distal side separately, and the score
of the worse side was counted.
Synovitis
Sites Synovitis was assessed in 11 regions [PIP (II–V),
MCP (I–V), the intercarpal and the distal
radioulnar joint].
Methods Synovitis was scored 0–3 according to the tertiles of
the STIR high signal regions in the synovial
compartment relative to the presumed maximum
volume:
0: normal (no synovitis), 1: mild, 2: moderate, 3:
severe.
The intercarpal joint score is doubled.
Proposed compact MRI score (cMRIS)
cMRIS = (total bone erosion points) 9 1.5 ? (total bone edema
points) 9 1.25 ? (total synovitis points) 9 1
PIP proximal interphalangea, MCP metacarpophalangea, CM carpo-
metacarpa, STIR short tau inversion recovery
Mod Rheumatol (2009) 19:358–365 361
123indicating clinical remission but a marked worsening of the
cMRIS (from 46.5 to 67.5).
Discussion
Rheumatoid arthritis is a chronic bone destruction disease
that severely and progressively afﬂicts the patient’s daily
activities. Biologics, including TNF blockers, have recently
Fig. 2 Serial changes in disease activity score on 28 joints (DAS28)
and compact MRI score (cMRIS) between ﬁrst (1st) and second (2nd)
MRI examinations. All patients except one had a good or moderate
response to the biologics, and none showed increased disease activity.
The cMRIS scores generally decreased or remained constant.
However, one patient of the inﬂiximab group showed an increase in
cMRIS score even under low disease activity (dotted line)
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123raised the hope of RA sufferers of dramatic improvements
in joint mobility and prognosis. The Trial of Etanercept and
Methotrexate with Radiographic Patient Outcomes
(TEMPO) study revealed the possibility of joint repair
through treatment with ETN plus methotrexate [11].
However, many such studies used conventional radiogra-
phy to evaluate bone erosion. Brown et al. [12] reported
that about 96% patients treated with conventional disease-
modifying antirheumatic drugs (DMARDs) achieved clin-
ical remission according to the criteria of the American
College of Rheumatology (ACR) and DAS28 score, but
they still showed synovitis as assessed by MRI. The same
percentage of asymptomatic patients with clinically normal
joints also had synovitis based on MRI, while 46% showed
bone marrow edema. In a comparative study on the ther-
apeutic effectiveness of DMARDs and anti-TNF biologics,
Martinez-Martinez et al. [13] also reported considerable
synovitis based on MRI scans. This was still the case even
in patients declared to be in clinical remission based on the
biologics. These authors also reported no signiﬁcant cor-
relation between the improvement of clinical or laboratory
data and MRI ﬁndings. Takes together, these studies stress
the necessity of including an MRI examination in order to
comprehensively evaluate total disease activity and joint
damage in RA.
The imaging position and time needed for whole-body
MRI makes it impractical for many rheumatologists to use
and burdensome for the patient. Low-ﬁeld extremity MRI
is thus a valuable alternative that has recently become
commercially available and has been tested for the diag-
nosis and monitoring of RA. Low-ﬁeld extremity MRI
improves patient comfort, is cost-effective for the institute,
and yields equivalent results to whole-body MRI in terms
of RA evaluation [14]. In support of this, using low-ﬁeld
extremity MRI, Savnik et al. [15] achieved a diagnostic
accuracy for synovitis, bone edema, and bone erosion in
RA comparable to that of high-ﬁeld MRI.
Crues et al. [16] further reported that low-ﬁeld dedi-
cated-extremity MRI is more sensitive for detecting erosive
changes in RA than radiography. In patients followed over
8 months, 30% demonstrated an increase in the size or
number of erosions by MRI, while radiography revealed
changes in only 0.8% of the patient cohort. Low-ﬁeld
dedicated-extremity MRI retains adequate imaging per-
formance, but at a lower cost and with greater comfort and
convenience for the patient. However, a limitation of low-
ﬁeld MRI is that the FOV is too small to enable an
assessment of the hands and wrists in one examination. As
wrist to PIP joints are usually affected in RA, examining
the wrist to hand in one sequence is important for diag-
nosing and monitoring RA. Another disadvantage is that
low-ﬁeld MRI systems are not practical for small clinics to
install because of their size and weight. To address these
limitations and to render MRI more useful for RA diag-
nosis and treatment, we have developed a new low-ﬁeld
extremity MRI. This system has a large enough FOV to
assess wrist to PIP joints in one examination, is lighter than
its predecessor, and requires less total area to install.
The general adoption of MRI in general practice has
also been hindered by a second problem. Many studies
have used the RAMRIS OMERACT scoring method for
MRI evaluation. However, this scoring method is too
complex for use in daily medical examinations and treat-
ments. We have used a new scoring system, cMRIS, for
evaluating disease activity in RA patients treated with anti-
TNF biologics. This method evaluates bone erosion, bone
edema, and synovitis as well as RAMRIS. The RAMRIS
scored bone erosion on a scale of 0–10 by its volume,
which may be inconvenient. In addition, the RAMRIS
method requires 2-D analysis. Therefore, we have
improved this point and developed cMRIS. The cMRIS
scores bone erosion on a scale of 0–3 by its volume, just as
the method used for edema and synovitis. Considering the
irreversibility of each ﬁnding, we decided that the coefﬁ-
cients for each ﬁnding should be 1.5 for bone erosion, 1.25
for bone edema, and 1 for synovitis. Based on the positive
correlation that we obtained between DDAS28 and
DcMRIS, we consider our scoring system to be useful in
linking MRI image evaluation to clinical evaluation.
However, a future large-scale study will be necessary to
examine whether these coefﬁcients are appropriate.
Another problem is that synovitis cannot be evaluated
precisely because we did not use gadolinium enhancement
in our MRI system. As gadolinium enhancement requires
intravenous injection and may induce severe side effects,
such as nephrogenic systemic ﬁbrosis, it cannot always be
used in daily practice, especially in a small clinic. The
problem of inaccuracy due to not using gadolinium can be
Fig. 3 Relationship between changes in the cMRIS value (DcMRIS)
and changes in the DAS28 (DDAS28). DcMRIS and DDAS28 are the
differences between the ﬁrst and the second images. A positive
correlation was observed between two evaluations (R = 0.55,
P\0.05)
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123solved to some extent through the acquisition of experi-
ence. As the aim of our study was to establish the evalu-
ation of RA disease activity by MRI in daily practice, we
did not use gadolinium enhancement and instead developed
an easier system to image and to facilitate the evaluations
of these images.
In almost all patients, a positive correlation was
observed between DDAS28 and DcMRIS. However, one
patient in the IFX group showed a worsening of bone
destruction when evaluated by cMRI even though the
estimated DAS28–CRP indicated clinical remission. Prior
to treatment, this patient had moderate disease activity
(DAS28–CRP 4.1). She then responded well to the treat-
ment and remained close to clinical remission during the
study. The MRI scan showed a DAS28–CRP of 2.66 at the
ﬁrst imaging and 2.83 at the second imaging. However,
both bone edema and erosion had worsened, as evidenced
by the MRI scan. This patients provides good proof of how
we can understand real disease activity using not only the
DAS28 but also the cMRI in daily practice. In the future,
rheumatologists should estimate real disease activity by
MRI and other tools in addition to clinical activity as
estimated by the DAS28.
Low-ﬁeld extremity MRI has been reported to record a
lower sensitivity than whole-body MRI in terms of bone
edema assessment [17], and different sensitivities have been
reported among different models [18]. We did not compare
our cMRI image and the 1.5-T whole-body MRI image.
However, work is now ongoing to develop an improved
system, the 0.3-T MRI machine, called the compacTscan,
which will enable a higher resolution and sensitivity imag-
ing, and a more precise diagnosis of RA. To date, we have
compared the 0.3-T cMRI image and the 1.5-T whole-body
MRI image in three patients and obtained almost the same
results (data not shown). The low-ﬁeld extremity MRI is
convenientforbothpatients andrheumatologists, anditsuse
in daily practice could assist clinicians both in making an
earlier diagnosis of RA and a more precise estimation of
disease activity. The hope is that joint prognosis of RA
patients will be improved using cMRI.
In conclusion, the results of our study have shown a
positive correlation between DcMRIS and DDAS28, sug-
gesting that cMRI and the cMRIS are useful for estimating
total disease activity and joint damage in RA.
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